After receiving a record number of nominations, we are pleased to announce our winners for the 2019 Buzz of BIO contest of the BIO Investor Forum!
WINNER: Early Stage Entrepreneur
SciBac creates live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. The company improves beneficial microorganisms by using its MERGE (Microbial Enhanced Recombinants Generated by Evolution) platform that can quickly, naturally and safely transfer useful genetic traits. The resulting microorganisms have the desired traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. By focusing on developing therapies for antibiotic resistant diseases, SciBac fills a rapidly increasing medical need.
WINNER: Late Stage Leader
Mycovia Pharmaceuticals develops therapies focused on women’s health. Its lead product candidate – VT-1161 – is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
WINNER: Diagnostics and Beyond 
X-Therma Biometric Nanotech halts ice formation through cryopreservation. By creating new molecules that are more effective than nature’s evolutionary response and more suitable for human applications, particularly in the regenerative medicine market, X-Therma seeks to improve the safety, efficacy and longevity of biostorage. The company’s frontier product, XT-Vivo™, is a state-of-the-art ice-blocking preservation solution that is DMSO-free, protein-free, serum-free, and chemically defined, set to transform the regenerative medicine market.
While the contest may be over, you can still apply to present at the BIO Investor Forum. Company presenters tend to receive twice as many BIO One-on-One PartneringTM meeting requests and schedule twice as many meetings compared to non-presenting companies, so apply today!
It’s also not too late to register for the BIO Investor Forum, October 22-23 in San Francisco, which focusses on investment opportunities for early stage and established private companies as well as emerging public companies. Learn more about the BIO Investor Forum, including registration, programming, company presentation and partnering information.
.png){kind=logo}
